Background/Aims: Recent studies suggest that markers of mesenteric inflammation, such as increased adipose tissue, may be associated with poor outcomes in Crohn's disease (CD). This study's hypothesis is that CD patients with metabolic syndrome (MetS) have more CD-related hospitalizations than CD patients without MetS. Methods: We conducted a retrospective cohort study of CD patients seen from 2000 to 2012 at our tertiary care center. We analyzed crude and age-, sex- and duration of CD-adjusted incidence rate ratio (IRR) of CD-related hospitalization of those with MetS versus those without MetS. We also investigated possible associations between individual component conditions of MetS and rate of CD-related hospitalization. Results: A total of 868 CD patients were included. There were 37 (4%) patients with MetS at initial observation. After multi-variable adjustment, patients with MetS had a CD-related hospitalization rate twice that of those who did not have MetS. High triglycerides (TG), low high density lipoprotein (HDL) cholesterol and diabetes mellitus (DM) were associated with increased risk of CD-related hospitalization. Conclusions: CD patients with MetS have a higher rate of CD-related hospitalization compared to those without MetS. Hypertriglyceridemia, low HDL cholesterol and DM may be good markers of local and systemic inflammation as seen in CD.

Journal Section:
Original Paper
Keywords:
Crohnߣs disease, Metabolic syndrome, Obesity, Dyslipidemia, Diabetes mellitus, Hypertension, Inflammatory bowel disease, Metabolic co-morbidities, Inflammatory markers, Hospitalization rate
1.
Calkins BM, Lilienfeld AM, Garland CF, Mendeloff AI: Trends in incidence rates of ulcerative colitis and Crohn's disease. Dig DisSci 1984;29:913-920.
[PubMed]
https://doi.org/10.1007/BF01312480
2.
Peyrin-Biroulet L, Chamaillard M, Gonzalez F, et al: Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander? Gut 2007;56:577-583.
[PubMed]
https://doi.org/10.1136/gut.2005.082925
3.
Olszanecka-Glinianowicz M, Handzlik-Orlik G, Orlik B, Chudek J: Adipokines in the pathogenesis of idiopathic inflammatory bowel disease. Endokrynol Pol 2013;64:226-231.
[PubMed]
4.
Alberti KG, Zimmet P, Shaw ZJ: Metabolic syndrome - a new world-wide definition. A consensus Statement from the International Diabetes Federation. Diabet Med 2006;23:469-480.
[PubMed]
https://doi.org/10.1111/j.1464-5491.2006.01858.x
5.
Ervin RB: Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl Health Stat Report 2009;13:1-7.
[PubMed]
6.
Bertin B, Desreumaux P, Dubuquoy L: Obesity, visceral fat and Crohn's disease. Curr Opin Clin Nutr Metab Care 2010;13:574-580.
[PubMed]
https://doi.org/10.1097/MCO.0b013e32833cf0f4
7.
Sappati Biyyani RS, Putka BS, Mullen KD: Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease. J Clin Lipidol 2010;4:478-482.
[PubMed]
https://doi.org/10.1016/j.jacl.2010.08.021
8.
Blain A, Cattan S, Beaugerie L, Carbonnel F, Gendre JP, Cosnes J: Crohn's disease clinical course and severity in obese patients. Clin Nutr 2002;21:51-57.
[PubMed]
https://doi.org/10.1054/clnu.2001.0503
9.
Dregan A, Charlton J, Chowienczyk P, Gulliford MC: Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study. Circulation 2014;130:837-844.
[PubMed]
https://doi.org/10.1161/CIRCULATIONAHA.114.009990
10.
Harper JW, Welch MP, Sinanan MN, Wahbeh GT, Lee SD: Co-morbid diabetes in patients with Crohn's disease predicts a greater need for surgical intervention. Aliment Pharmacol Ther 2012;35:126-132.
[PubMed]
https://doi.org/10.1111/j.1365-2036.2011.04915.x
11.
Nagahori M, Hyun SB, Totsuka T, et al: Prevalence of metabolic syndrome is comparable between inflammatory bowel disease patients and the general population. J Gastroenterol 2010;45:1008-1013.
[PubMed]
https://doi.org/10.1007/s00535-010-0247-z
12.
Ripolles Piquer B, Nazih H, Bourreille A, et al: Altered lipid, apolipoprotein, and lipoprotein profiles in inflammatory bowel disease: consequences on the cholesterol efflux capacity of serum using Fu5AH cell system. Metabolism 2006;55:980-988.
[PubMed]
https://doi.org/10.1016/j.metabol.2006.03.006
13.
Mendall MA, Gunasekera AV, John BJ, et al: Is obesity a risk factor for Crohn's disease? Dig Dis Sci 2011;56:837-844.
[PubMed]
https://doi.org/10.1007/s10620-010-1541-6
14.
Levy E, Rizwan Y, Thibault L, et al: Altered lipid profile, lipoprotein composition, and oxidant and antioxidant status in pediatric Crohn disease. Am J Clin Nutr 2000;71:807-815.
[PubMed]
15.
Zaninotto P, Falaschetti E: Comparison of methods for modelling a count outcome with excess zeros: application to activities of daily living (ADL-s). J Epidemiol Community Health 2011;65:205-210.
[PubMed]
https://doi.org/10.1136/jech.2008.079640
16.
Bitzur R, Cohen H, Kamari Y, Shaish A, Harats D: Triglycerides and HDL cholesterol: stars or second leads in diabetes? Diabetes Care 2009;32(suppl 2):S373-S377.
[PubMed]
https://doi.org/10.2337/dc09-S343
17.
Nguyen GC, Tuskey A, Dassopoulos T, Harris ML, Brant SR: Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004. Inflamm Bowel Dis 2007;13:1529-1535.
[PubMed]
https://doi.org/10.1002/ibd.20250
18.
Bewtra M, Su C, Lewis JD: Trends in hospitalization rates for inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol 2007;5:597-601.
[PubMed]
https://doi.org/10.1016/j.cgh.2007.01.015
© 2015 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2015
You do not currently have access to this content.